Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up…
Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up…
Newleos Therapeutics has closed an oversubscribed Series A financing round, raising $93.5m to revolutionise neuropsychiatric disorder treatments with new medicines.…
SmartCella has secured exclusive rights to advance research into cell replacement therapies for the treatment of Parkinson's disease (PD). The…
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’…
The University of Southern California (USC) has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to…
The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's Leqembi (lecanemab-irmb)…
Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for trofinetide, aimed at treating…
Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi…
Neumora Therapeutics saw a drop of more than 80% in its share price following the announcement of a Phase III…
Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, aimed at…